DHR – Danaher’s Q1 results suggest the recovery is becoming clearer, although growth is still uneven across business segments. 🧪 Danaher started 2026 with $6.0 billion in revenue, up 3.5% year over year, while adjusted EPS came in at $2.06 and clearly beat market expectations. Free cash flow remained solid at $1.1 billion, reinforcing the view that earnings quality is still holding up well. 📈 The biggest strength came from Biotechnology, where core growth reached 7.0%, while Life Sciences rose 0.5% and performed slightly better than expected. On the other side, Diagnostics declined 4.0% as Cepheid’s respiratory season was softer than usual, leaving the overall growth picture still somewhat uneven. 🧭 Management also slightly raised full-year adjusted EPS guidance to $8.35–$8.55 and kept its core revenue growth outlook at 3% to 6%, signaling stronger confidence in the 2026 recovery path. The planned Masimo acquisition adds another growth angle, although the market reaction so far has remained only moderately positive. #HealthcareStocks #EarningsUpdate